Menumenu
  • Home
  • Resource Library

Resource Library

publications • bibliographies • white papers

All Publications

  • No decreased risk of gastrointestinal cancers in users of metformin in The Netherlands; a time-varying analysis of metformin exposureAbstract

    Previous studies on metformin use and gastrointestinal (GI) cancer risk have yielded inconclusive results on metformin’s chemoprotective effects. We aimed to evaluate GI cancer risk in users of metformin in The Netherlands using a time-varying apprach in a large population-based database. A cohort study was performed using the NCR-PHARMO database

    deJong RG, Burden AM, deKort S, van Herk-Sukel M, Vissers PA, Janssen PK, Haak HR, Masclee AA, deVries F, Janssen-Heijnen ML. Cancer Prev Res (Phila). 2017 Mar 08;
  • Use of Lipid-Modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the NetherlandsAbstract

    PURPOSE: This study investigates lipid-modifying therapy (LMT) and LDL-C goal attainment in a real-world, high-cardiovascular-risk population in the Netherlands. METHODS: From the PHARMO Database Network, patients aged >/=18 years with an LDL-C meaurement in 2012 (index date) were selected and hierarchically classified into the following mutually exclusive high-cardiovascular-risk categories: familial hypercholesterolemia (FH), recent acute coronary syndrome (ACS), coronary heart disease, ischemicstroke, peripheral arterial disease, and diabetes mellitus

    Kuiper JG, Sanchez RJ, Houben E, Heintjes EM, Penning-van Beest FJ, Khan I, van Riemsdijk M, Herings RM. Clin Ther. 2017 Mar 24; 819 - 827.
  • Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-Based Multi-Database StudyAbstract

    PURPOSE: The aim of this study was to determine the similarities and differences of type 2 diabetes mellitus (T2DM) treatment patterns in daily practice in 5 European countries and whether these reflect differences in guidelines. METHODS: Prescriptons for drugs used in diabetes treatment during a 5-year study period were obtained from electronic databases

    Overbeek JA, Heintjes EM, Prieto-Alhambra D, Blin P, Lassalle R, Hall GC, Lapi F, Bianchini E, Hammar N, Bezemer ID, Herings RM. Clin Ther. 2017 Mar 22; 39 759-770.
  • Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control studyAbstract

    PURPOSE: To assess the risk of gastrointestinal perforation, ulcers, or bleeding (PUB) associated with the use of conventional nonsteroidal anti-inflammatory drugs (NSAIDs) with proton pump inhibitors (PPIs) and selective COX-2 inhibitors, with orithout PPIs compared with conventional NSAIDs. METHODS: A case-control study was performed within conventional NSAIDs and/or selective COX-2 inhibitors users identified from the Dutch PHARMO Record Linkage System in the period 1998-2012

    Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. Pharmacoepidemiol Drug Saf. 2017 Mar 31; 1141-1148.
  • The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancerAbstract

    BACKGROUND: Several studies have suggested that the association between aspirin and improved cancer survival is mediated through the mechanism of aspirin as thrombocyte aggregation inhibitors (TAI). The aim of this study was to provide epidemiologial evidence for this mechanism assessing the association between overall survival and the use of aspirin and non-aspirin TAI in patients with colorectal cancer

    Frouws MA, Rade maker E, Bastiaannet E, van Herk-Sukel MP, Lemmens VE, Vande Velde CJ, Portielje JE, Liefers GJ. Eur J Cancer. 2017 Mar 25; 77 24-30.
  • Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year periodAbstract

    AIMS: The aims of the present study were to assess antiplatelet drug use patterns after a first myocardial infarction (MI) and to evaluate the determinants of antiplatelet nonpersistence. METHODS: The present study was conducted in 4690 patients frm the Utrecht Cardiovascular Pharmacogenetics cohort with a first MI between 1986 and 2010, who were followed for a maximum of 10 years

    Yasmina A, de Boer A, Deneer VH, Souverein PC, Klungel OH. Br J Clin Pharmacol. 2017 Mar; 83 (3): 632-641.
  • Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomesAbstract

    Information on treatment patterns for ovarian cancer (OC) is limited. The aim of this study was to describe current patterns of chemotherapy and other systemic treatments for OC in the Netherlands and evaluate survival outcomes following subsequentlines of treatment. Data from the Eindhoven Cancer Registry, including on newly diagnosed cancer patients, were linked to the PHARMO Database Network, including information on in- and out-patient drug use

    Houben E, van Haalen HG, Sparreboom W, Overbeek JA, Ezendam NP, Pijnenborg JM, Severens JL, van Herk-Sukel MP. Med Oncol. 2017 Apr; 34 (4): 50.
  • No association between metformin use and survival in patients with pancreatic cancer: An observational cohort studyAbstract

    Several studies have suggested an association between use of metformin and an increased overall survival in patients diagnosed with pancreatic cancer, however with several important methodological limitations. The aim of the study was to assess theassociation between overall survival, pancreatic cancer, and metformin use

    Frouws MA, Mulder BG, Bastiaannet E, Zander s MM, van Herk-Sukel MP, deLeede EM, Bonsing BA, Mieog JS, VandeVelde CJ, Liefers GJ. Medicine (Baltimore). 2017 Mar; 96 (10): e6229.
  • Chemotherapy Exposure and outcomes of Chronic Lymphoid Leukemia PatientsAbstract

    Kuiper J, Musingarimi P, Tapprich C, Penning-van Beest F, Gaudig M. J Clin Intensive Care Med. 2017 2 025-033.
  • Prevalence of diabetes mellitus in the Netherlands more than doubled in the period 1999-2014Abstract

    OBJECTIVE: To study the trend in the prevalence of diabetes in the Netherlands during the period 1999-2014. DESIGN: Descriptive study of prevalence. METHODS: The prevalence of diabetes during the period 1999-2014 was calculated on the basis of datafrom the PHARMO Database Network, a network of electronic databases that includes data from public pharmacies for 3

    Overbeek JA, van der Heijden AW, Herings RM, Nijpels G. Ned Tijdschr Geneeskd. 2017 161 D673.